Boule Diagnostics approves loan from major shareholder
The decision was made at the extraordinary general meeting and ensures capital injection through AB Grenspecialisten according to the board's proposal.
See the latest news and media coverage for Boule. We track all announcements, press releases, and industry mentions in real time, all in one place.
Hematology and clinical chemistry diagnostics provider
boule.comLast updated
In short: Boule appointed Johan Folkunger as CEO, reported a 13.3% drop in Q2 2026 sales, and authorized a loan from its major shareholder.
The decision was made at the extraordinary general meeting and ensures capital injection through AB Grenspecialisten according to the board's proposal.
An extraordinary general meeting will be held on 31 August to decide on approval of a loan from AB Grenspecialisten.
Adjusted operating profit decreased to MSEK 3.3, affected by geopolitical disturbance and new CEO took office.
He succeeds Simonetta Tumbiolo and starts June 22, 2026.
17/07 Boule Diagnostics AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026 CI 17/07 Bourse de...
This article first appeared on GuruFocus. Release Date: July 17, 2026 For the complete transcript of the earnings call, please refer to the full earnings...
Boule Diagnostics AB ( (SE:BOUL) ) just unveiled an announcement.
The diagnostics company Boule Diagnostics has appointed Simonetta Tumbiolo, currently Chief Commercial Officer Diagnostic, as acting CEO from June 1.
Track Boule and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Boule and other trending companies.